Thursday, July 27, 2023 12:54:46 PM
Simply take a look how many tumor associated peptides that the MHC Class 2 molecules on the surface of dendritic cells can present to the immune system. Go through these cancer vaccine companies using neo-antigen technology or mRNA technology. Will these companies be able to present huge number of peptides so that t-cells can have fully comprehensive data to identify which cell is cancer cell and which cell is normal cell? None of them can.
These cancer vaccine companies at most can only present less than 50 tumor-specific peptides to the immune system. More importantly, at best they can only activate CD8 t cells which will not trigger immune memory.
Recent NVCR News
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
